Local Coverage Article:
MolDX: Abbott RealTime IDH2 testing for Acute Myeloid Leukemia (AML) Billing and Coding Guidelines (A55711)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

---

**Contractor Information**

<table>
<thead>
<tr>
<th>Contractor Name</th>
<th>Contract Type</th>
<th>Contract Number</th>
<th>Jurisdiction</th>
<th>State(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01111 - MAC A</td>
<td>J - E</td>
<td>California - Entire State</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01112 - MAC B</td>
<td>J - E</td>
<td>California - Northern</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01182 - MAC B</td>
<td>J - E</td>
<td>California - Southern</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01211 - MAC A</td>
<td>J - E</td>
<td>American Samoa</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01212 - MAC B</td>
<td>J - E</td>
<td>Guam</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01311 - MAC A</td>
<td>J - E</td>
<td>Nevada</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01312 - MAC B</td>
<td>J - E</td>
<td>Northern Mariana Islands</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01911 - MAC A</td>
<td>J - E</td>
<td>American Samoa</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01912 - MAC B</td>
<td>J - E</td>
<td>Guam</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01913 - MAC A</td>
<td>J - E</td>
<td>Hawaii</td>
</tr>
<tr>
<td>Noridian Healthcare Solutions, LLC</td>
<td>A and B MAC</td>
<td>01914 - MAC B</td>
<td>J - E</td>
<td>Northern Mariana Islands</td>
</tr>
</tbody>
</table>

---

**Article Information**

**General Information**

<table>
<thead>
<tr>
<th>Article ID</th>
<th>Original Article Effective Date</th>
<th>Revision Effective Date</th>
<th>Revision Ending Date</th>
<th>Retirement Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>A55711</td>
<td>10/15/2017</td>
<td>01/01/2018</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Article Title**
MolDX: Abbott RealTime IDH2 testing for Acute Myeloid Leukemia (AML) Billing and Coding Guidelines

**AMA CPT / ADA CDT / AHA NUBC Copyright Statement**
CPT only copyright 2002-2018 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
Article Guidance

Article Text:

At the current time, the Abbott RealTime IDH2 by Abbott Molecular is the only test that has received FDA approval to be used as an aid in identifying acute myeloid leukemia (AML) patients with an isocitrate dehydrogenase-2 mutation for treatment with enasidenib (IDHIFA®).

IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.

To report an Abbott RealTime IDH2 service, please submit the following claim information:

- Enter 1 unit of service (UOS)
- Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part B claim field/types:
  - Loop 2400 or SV101-7 for the 5010A1 837P
  - Item 19 for paper claim
- Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part A claim field/types:
  - Line SV202-7 for 837I electronic claim
  - Block 80 for the UB04 claim form
- Select the appropriate ICD-10-CM code

Note: This MolDX coverage determination and coding guideline ONLY applies to the UNMODIFIED, IDH2 test kit by Abbott Molecular for patients with acute myeloid leukemia. If a lab modifies these tests, a MolDX Technical Assessment, outlined in the MolDx section on www.PalmettoGBA.com/medicare, must be submitted and a determination assessed prior to claims submission.

This article reflects the FDA-approved indications on article creation date. MolDX will allow future FDA approved and amended indications for these tests.

Coding Information

Bill Type Codes:
Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the article should be assumed to apply equally to all claims.

N/A

**Revenue Codes:**

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the article should be assumed to apply equally to all Revenue Codes.

N/A

**CPT/HCPCS Codes**

*Group 1 Paragraph: N/A*

**Group 1 Codes:**

- **Group 1 CPT/HCPCS Code**
- **Group 1 CPT/HCPCS Code Description**
  - 81121: IDH2 (ISOCITRATE DEHYDROGENASE 2 [NADP+], MITOCHONDRIAL) (EG, Glioma), common variants (EG, R140W, R172M)

**ICD-10 Codes that are Covered**

*Group 1 Paragraph: N/A*

**Group 1 Codes:**

- ICD-10 Codes that are covered Information Table
  - **Code**
  - **Description**
  - C92.00: Acute myeloblastic leukemia, not having achieved remission
  - C92.02: Acute myeloblastic leukemia, in relapse

**ICD-10 Codes that are Not Covered**

N/A

[Back to Top]

**Revision History Information**

<table>
<thead>
<tr>
<th>Revision History Date</th>
<th>Revision History Number</th>
<th>Revision History Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>01/01/2018</td>
<td>R1</td>
<td>Article is revised to replace 81403 with 81121, effective 1/1/2018.</td>
</tr>
</tbody>
</table>

[Back to Top] **Related Local Coverage Document(s)** LCD(s) L35160 - MolDX: Molecular Diagnostic Tests (MDT)

**Related National Coverage Document(s)** N/A

**Statutory Requirements URL(s)** N/A

**Rules and Regulations URL(s)** N/A

**CMS Manual Explanations URL(s)** N/A

**Other URL(s)** N/A

**Public Version(s)** Updated on 07/03/2018 with effective dates 01/01/2018 - N/A Updated on 08/23/2017 with

Printed on 7/16/2018. Page 3 of 4
Keywords

- Abbott
- IDH2
- AML
- Myeloid
- leukemia
- 81121
- MolDX
- 
- 

Read the Article Disclaimer Back to Top